AbbVie reported first-quarter 2026 worldwide net revenues of $15.002 billion, up 12.4% on a reported basis, and raised its full-year adjusted diluted EPS guidance to $14.08–$14.28. The company posted GAAP diluted EPS of $0.39 and adjusted diluted EPS of $2.65, which beat internal expectations despite a $0.41 per share unfavorable impact from acquired IPR&D and milestone expenses. Separately, Allergan Aesthetics announced European Commission approval of Boey, the first rapid-onset, short-duration botulinum neurotoxin serotype E in Europe, across all 30 European Economic Area countries. Canaccord raised its price target on AbbVie to $282 from $273 while maintaining a Buy rating, citing expected strength in core prescription volumes and recent developmental wins. Hedge fund data tracked by Insider Monkey showed 87 funds held AbbVie positions in Q1 2026, up from 84 in Q4 2025.
AbbVie IncRaises 2026 EPS guidance and beats Q1 expectations
